{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:44:58Z","timestamp":1791953098922,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01019-6","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:59:01Z","timestamp":1791925141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid Serum IgG Reduction as a Potential Indicator of Short-Term Clinical Improvement in AChR-Ab-Positive Generalized Myasthenia Gravis: A Post\u00a0Hoc Analysis of a Phase\u00a0III Batoclimab Trial"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct05039190","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zhijun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoxian","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruisheng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haishan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangyu","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglong","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianquan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9106-0361","authenticated-orcid":false,"given":"Bitao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"5","key":"1019_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, et al. Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12(5):259\u201368. https:\/\/doi.org\/10.1038\/nrneurol.2016.44.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"1019_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1019_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","volume":"21","author":"MG Huijbers","year":"2022","unstructured":"Huijbers MG, Marx A, Plomp JJ, et al. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):163\u201375. https:\/\/doi.org\/10.1016\/S1474-4422(21)00357-4.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1019_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/1744-9987.14065","volume":"28","author":"S Konno","year":"2023","unstructured":"Konno S, Fujioka T. Serum immunoglobulin\u00a0G level reduction is a predictor of short-term improvement in patients with myasthenia gravis undergoing plasmapheresis. Ther Apher Dial. 2023;28(1):131\u201340. https:\/\/doi.org\/10.1111\/1744-9987.14065.","journal-title":"Ther Apher Dial"},{"key":"1019_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2203","author":"L Wang","year":"2021","unstructured":"Wang L, Wang S, Yang H, et al. No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: a systematic retrospective study involving 67 patients. Brain Behav. 2021. https:\/\/doi.org\/10.1002\/brb3.2203.","journal-title":"Brain Behav"},{"issue":"9","key":"1019_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/jnnp-2020-325511","volume":"92","author":"Y Kojima","year":"2021","unstructured":"Kojima Y, Uzawa A, Ozawa Y, et al. Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome. J Neurol Neurosurg Psychiatry. 2021;92(9):963\u20138. https:\/\/doi.org\/10.1136\/jnnp-2020-325511.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1019_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420935697","author":"F Aguirre","year":"2020","unstructured":"Aguirre F, Manin A, Fernandez VC, et al. C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis. Ther Adv Neurol Disord. 2020. https:\/\/doi.org\/10.1177\/1756286420935697.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"1019_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/jca.21694","volume":"34","author":"A Usmani","year":"2019","unstructured":"Usmani A, Kwan L, Wahib-Khalil D, et al. Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status. J Clin Apheresis. 2019;34(4):416\u201322. https:\/\/doi.org\/10.1002\/jca.21694.","journal-title":"J Clin Apheresis"},{"issue":"4","key":"1019_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","volume":"49","author":"DB Sanders","year":"2014","unstructured":"Sanders DB, Burns TM, Cutter GR, et al. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve. 2014;49(4):483\u20136. https:\/\/doi.org\/10.1002\/mus.23944.","journal-title":"Muscle Nerve"},{"issue":"12","key":"1019_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase\u00a03, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1.","journal-title":"Lancet Neurol"},{"key":"1019_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis. JAMA Neurol. 2022. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1019_CR12","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","volume":"271","author":"J Li","year":"2024","unstructured":"Li J, Wu X, Chu T, et al. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2024;271(5):2298\u2013308. https:\/\/doi.org\/10.1007\/s00415-024-12247-x.","journal-title":"J Neurol"},{"key":"1019_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207937","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V, et al. Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis. Neurology. 2024. https:\/\/doi.org\/10.1212\/WNL.0000000000207937.","journal-title":"Neurology"},{"issue":"5","key":"1019_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase\u00a03 study. Lancet Neurol. 2023;22(5):383\u201394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1019_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","volume":"11","author":"C Yan","year":"2022","unstructured":"Yan C, Duan R-S, Yang H, et al. Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase\u00a0II study. Neurol Ther. 2022;11(2):815\u201334. https:\/\/doi.org\/10.1007\/s40120-022-00345-9.","journal-title":"Neurol Ther"},{"issue":"7","key":"1019_CR16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2021;20(7):526\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1019_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","volume":"38","author":"Y Ma","year":"2024","unstructured":"Ma Y, Nie X, Zhu G, et al. The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis. CNS Drugs. 2024;38(2):93\u2013104. https:\/\/doi.org\/10.1007\/s40263-024-01062-7.","journal-title":"CNS Drugs"},{"issue":"4","key":"1019_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","volume":"81","author":"C Yan","year":"2024","unstructured":"Yan C, Yue Y, Guan Y, et al. Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trail. JAMA Neurol. 2024;81(4):336\u201345. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0044.","journal-title":"JAMA Neurol"},{"key":"1019_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1505464","author":"B Smith","year":"2018","unstructured":"Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs. 2018. https:\/\/doi.org\/10.1080\/19420862.2018.1505464.","journal-title":"MAbs"},{"issue":"1","key":"1019_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/1759-7714.13724","volume":"12","author":"A De Rosa","year":"2020","unstructured":"De Rosa A, Fornili M, Maestri Tassoni M, et al. Thymoma-associated myasthenia gravis: clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma. Thorac Cancer. 2020;12(1):106\u201313. https:\/\/doi.org\/10.1111\/1759-7714.13724.","journal-title":"Thorac Cancer"},{"issue":"4","key":"1019_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/ene.15238","volume":"29","author":"F Marcuse","year":"2022","unstructured":"Marcuse F, Brandts L, Moens D, et al. The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis. Eur J Neurol. 2022;29(4):1187\u201397. https:\/\/doi.org\/10.1111\/ene.15238.","journal-title":"Eur J Neurol"},{"key":"1019_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2026.115682","volume":"400","author":"T Zhou","year":"2026","unstructured":"Zhou T, Zhang C, Lu Y, Qiao S, Zhang S. Disease models of anti-N-methyl-d-aspartate receptor encephalitis: investigating pathogenesis and targeted therapy. Exp Neurol. 2026;400:115682. https:\/\/doi.org\/10.1016\/j.expneurol.2026.115682.","journal-title":"Exp Neurol"},{"key":"1019_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","volume":"24","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase\u00a03, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24:105\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(24)00498-8.","journal-title":"Lancet Neurol"},{"key":"1019_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011108","author":"V Bril","year":"2021","unstructured":"Bril V, Benatar M, Andersen H, et al. Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis. Neurology. 2021. https:\/\/doi.org\/10.1212\/WNL.0000000000011108.","journal-title":"Neurology"},{"key":"1019_CR25","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.28.24312367","author":"F Khani-Habibabadi","year":"2024","unstructured":"Khani-Habibabadi F, Roy B, Pham MC, et al. Distribution and temporal changes of autoantibody-mediated pathogenic mechanisms among acetylcholine receptor-positive myasthenia gravis patients. medRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.08.28.24312367.","journal-title":"medRxiv"},{"issue":"2","key":"1019_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham MC, Masi G, Patzina R, et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 2023;146(2):319\u201336. https:\/\/doi.org\/10.1007\/s00401-023-02603-y.","journal-title":"Acta Neuropathol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01019-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:49:14Z","timestamp":1791949754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01019-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":26,"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01019-6","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Chongbo Zhao served as principal investigator for this trial. Chen Zong and Shuai Zhao are employees of Nona Biosciences (Suzhou), a subsidiary of Harbour BioMed Inc. The remaining authors Zhijun Li, Qing Ke, Jianying Xi, Yaoxian Yue, Yuzhou Guan, Ruisheng Duan, Qun Xue, Haishan Jiang, Fei Xiao, Huan Yang, Ting Chang, Zhangyu Zou, Haifeng Li, Song Tan, Haibing Xiao, Hongyu Zhou, Hua Zhang, Qiang Meng, Wenyu Li, Wei Li, Junhong Guo, Yali Zhang, Zunbo Li, Jianglong Tu, Jianquan Shi, Wei Li, Hui Deng, Bitao Bu disclose no conflicts.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was registered on ClinicalTrials.gov (NCT05039190) and conducted in accordance with the Declaration of Helsinki of 1964 and its later amendments. The protocol was approved by the ethics committees of all participating centers; details of ethical approval dates and numbers are provided in the supplementary table. Written informed consent was obtained from all participants prior to any study-related procedures.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}